GlassScriptPhysician profile
Michael A Velasquez
NPI 1639161698
$2,792.73
in general payments reported to CMS, 2019-2025
20 companies · $622 in 2025
The $622 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43.60 · 2021: $14.06 · 2022: $703 · 2023: $638 · 2024: $772 · 2025: $622.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,032.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,031.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $507.27 | 2022-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $474.52 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $429.89 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $348.30 | 2022-2024 | Jardiance |
| Lilly USA, LLC | $310.60 | 2022-2025 | Mounjaro, Zepbound |
| Amgen INC. | $147.14 | 2022-2024 | Krystexxa |
| Mylan Specialty L.P. | $125.01 | 2023 | Yupelri |
| Exact Sciences Corporation | $123.85 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $68.62 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.17 | 2022-2025 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $25.82 | 2022-2023 | Seglentis, Livalo |
| Shire North American Group INC | $24.96 | 2019 | |
| Dexcom, INC. | $24.06 | 2023 | Dexcom G6 Transmitter |
| Travere Therapeutics, INC. | $21.65 | 2023 | |
| Sunovion Pharmaceuticals INC. | $18.64 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $18.64 | 2022 | |
| Merck Sharp & Dohme LLC | $18.04 | 2025 | Bridion |
| Amarin Pharma, INC. | $18.03 | 2022 | |
| Xeris Pharmaceuticals, INC. | $16.89 | 2025 | Gvoke Hypopen |
| Pfizer INC. | $16.63 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Velasquez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.